نتایج جستجو برای: peptide vaccine

تعداد نتایج: 263016  

Journal: :The Journal of veterinary medical science 1997
S Kawazu T Okumura Y Hirogari T Miyahara Y Terasaka M Hida Y Terada T Kamio K Fujisaki

A polymorphism in the experimentally successful peptide vaccine sequence (EVVWKEKKEVKDLDA, amino acids 134-148) derived from the 33 kDa piroplasm major surface antigen (p33) of Theileria sergenti was examined. The vaccine sequences obtained by PCR amplification and sequencing of the p33 gene from a total of 15 parasite-infected cattle blood samples collected from 4 prefectures through Hokkaido ...

2011
Aiala Salvador Manoli Igartua Rosa Maria Hernández José Luis Pedraz

The development of synthetic peptide-based vaccines has many advantages in comparison with vaccines based on live attenuated organisms, inactivated or killed organism, or toxins. Peptide-based vaccines cannot revert to a virulent form, allow a better conservation, and are produced more easily and safely. However, they generate a weaker immune response than other vaccines, and the inclusion of a...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Craig L Slingluff Gina R Petroni Kimberly A Chianese-Bullock Mark E Smolkin Sarah Hibbitts Cheryl Murphy Naomi Johansen William W Grosh Galina V Yamshchikov Patrice Y Neese James W Patterson Robyn Fink Patrice K Rehm

PURPOSE Human melanoma cells express shared antigens recognized by CD8(+) T lymphocytes, the most common of which are melanocytic differentiation proteins and cancer-testis antigens. However, peptide vaccines for melanoma usually target only one or two MHC class I-associated peptide antigens. Because melanomas commonly evade immune recognition by selective antigen loss, optimization of melanoma...

Journal: :Frontiers in bioscience : a journal and virtual library 2005
Ken S Rosenthal

Vaccines optimize the presentation of an immunogen to the immune system, oftentimes enhancing or replacing the natural activators of antigen presenting cells in order to promote the delivery and the response of T and B lymphocytes to the immunogen. The purpose of this series is to describe new technologies which allow vaccine design, based on our understanding of the immune response, using diff...

2013
Daisuke Nobuoka Toshiaki Yoshikawa Yu Sawada Toshiyoshi Fujiwara Tetsuya Nakatsura

Immunotherapy is a potentially attractive treatment option for patients with hepatocellular carcinoma (HCC). We have reported that glypican-3 (GPC3) is an ideal target for anticancer immunotherapy against HCC because its expression is specifically detected in > 80% of HCCs, even during the early stages. Further, increased GPC3 expression is correlated with a poor prognosis. Based on results obt...

2015
Pengfei Jiang Wangqi Du Yirong Xiong Yan Lv Juan Feng Shanli Zhu Xiangyang Xue Shao Chen Lifang Zhang

Chlamydia trachomatis (Ct) is the leading cause of sexually transmitted diseases worldwide. There is no safe and effective vaccine to control the spread of Ct. In development of Ct vaccine, selection of appropriate candidate antigens and an effective delivery system may be the main challenges. Multi-epitope of major outer membrane protein (MOMPm) is the most suitable candidate for a Ct vaccine,...

2017
Nobuhiro Tsuchiya Toshiaki Yoshikawa Norihiro Fujinami Keigo Saito Shoichi Mizuno Yu Sawada Itaru Endo Tetsuya Nakatsura

We have previously conducted a phase I trial to test the efficacy of a glypican-3 (GPC3) peptide vaccine in patients with advanced hepatocellular carcinoma (HCC); however, its immunological mechanism of action remains unclear. Here, we report a pilot study conducted to evaluate the immunological mechanisms of action of this GPC3 peptide vaccine (UMIN-CTR number 000005093). Eleven patients with ...

Streptococcal bacteria are among dangerous human pathogens with major prevalence worldwide. A good vaccine against streptococcal bacteria should have epitopes that confer protection from infection by different streptococcal bacteria types. we aimed was to recognize the most immunogenic and conserved epitopes of streptococcal bacteria, which could be a potential candidate for vaccine development...

Journal: :Journal of immunology 2013
Kevin Chu Foy Ruthie M Wygle Megan J Miller Jay P Overholser Tanios Bekaii-Saab Pravin T P Kaumaya

Epidermal growth factor receptor (EGFR) is a validated target for several cancers including lung, colorectal, and certain subtypes of breast cancer. Cetuximab targets ligand binding of EGFR, but major problems like high cost, short t1/2, toxicity, and emergence of resistance are associated with the drug. Immunization with EGFR B cell epitopes will train the immune system to produce specific Abs...

2016
Yusuke Oji Naoya Hashimoto Akihiro Tsuboi Yui Murakami Miki Iwai Naoki Kagawa Yasuyoshi Chiba Shuichi Izumoto Olga Elisseeva Ryo Ichinohasama Junichi Sakamoto Satoshi Morita Hiroko Nakajima Satoshi Takashima Yoshiki Nakae Jun Nakata Manabu Kawakami Sumiyuki Nishida Naoki Hosen Fumihiro Fujiki Soyoko Morimoto Mayuko Adachi Masahiro Iwamoto Yoshihiro Oka Toshiki Yoshimine Haruo Sugiyama

We previously evaluated Wilms' tumor gene 1 (WT1) peptide vaccination in a large number of patients with leukemia or solid tumors and have reported that HLA-A*24:02 restricted, 9-mer WT1-235 peptide (CYTWNQMNL) vaccine induces cellular immune responses and elicits WT1-235-specific cytotoxic T lymphocytes (CTLs). However, whether this vaccine induces humoral immune responses to produce WT1 antib...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید